spot_img
Friday, May 20, 2022
More
    HomeHealthBlueprint Medicines seeks 'continuity, not change' in CEO transition

    Blueprint Medicines seeks ‘continuity, not change’ in CEO transition

    -

    [ad_1]

    For Jeff Albers, the choice to step down because the CEO of Blueprint Medicines after eight years is a “pure evolution” for the rising biotech firm that permits different executives to step up into extra senior roles.

    In a management transition introduced Wednesday, Albers will exit his CEO put up in April however will stay with Blueprint as govt chairman. Present Chief Working Officer Kate Haviland was promoted to CEO. Christina Rossi, the corporate’s chief industrial officer, will transfer into Haviland’s former COO function.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!

    GET STARTED



    [ad_2]

    Source link

    Related articles

    Stay Connected

    0FansLike
    0FollowersFollow
    3,322FollowersFollow
    0SubscribersSubscribe
    spot_img

    Latest posts